Verified employee & interview reviews

MedGenome Reviews

Bengaluru, Karnataka

4.7/ 5

3 reviews

MedGenome is a leading genomics-driven diagnostics and research services company dedicated to improving global health by decoding genetic information. Founded in April 2013 by Sam Santhosh, Mahesh Pratapneni, and Sreedhar Santhosh, the company is headquartered in Bengaluru, Karnataka, India, and maintains a significant global footprint with corporate offices and high-throughput Next-Generation Sequencing (NGS) facilities in Foster City, California, alongside operations in Singapore and Africa. MedGenome operates as the market leader for genetic diagnostics in South Asia, applying cutting-edge multiomics technologies, bioinformatics, and big data analytics to understand complex conditions at the genetic and molecular level. The company's core operations are structured around three primary business segments: diagnostics, research services, and data licensing solutions. In its diagnostics division, MedGenome offers an extensive menu of over 1,300 advanced genetic tests across major clinical categories, including oncology, inherited disorders, reproductive health, infectious diseases, and metabolic conditions. Its specialized sub-brands include Claria for non-invasive prenatal screening and reproductive genetics, Actia for inherited and rare disease testing, and Genessense, a direct-to-consumer division launched in 2021 that focuses on preventive wellness and genetic susceptibility to lifestyle diseases. On the research and data licensing front, the company provides robust bioinformatics pipelines and has developed proprietary platforms such as OncoPept, a cancer immunotherapy solution, and Modmab, an immunology platform. These platforms are licensed to global pharmaceutical and biotechnology companies to accelerate biomarker identification and drug discovery programs. MedGenome’s operational scale is anchored by South Asia's largest College of American Pathologists (CAP)-accredited and NABL-certified genomics sequencing laboratory located in Bengaluru. Over the past decade, the company has sequenced more than 500,000 exomes and genomes, establishing the largest database of South Asian genetic variants. It has built a vast healthcare infrastructure network consisting of over 24,000 clinicians and 8,000 partnered hospitals, delivering clinical testing services across more than 600 locations pan-India and in about 40 countries worldwide. The company is also a founding member of the GenomeAsia 100K initiative, an international collaboration aiming to sequence 100,000 genomes across Asia. Financially, MedGenome operates as a well-funded private entity, having raised a total of $264 million in funding over ten investment rounds. Its financing includes a recent Series E expansion round co-led by Danish private equity firm Maj Invest and existing investor Novo Holdings, with continued participation from Sofina, alongside backing from other institutional investors like Peak XV Partners, LeapFrog Investments, and HDFC Bank. Led by Chief Executive Officer Vedam Ramprasad and Board Chairman Dr. Amit Kakar, MedGenome employs over 1,300 people, including a specialized talent pool of more than 200 scientific experts, genome analysts, and bioinformatics engineers. The company remains committed to advancing precision medicine, expanding its integrated diagnostics footprint, and making genomic healthcare affordable, accessible, and equitable globally.